We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current ABUS market cap is 606.99M. The company's latest EPS is USD -0.3805 and P/E is -8.30.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 5.01M | 4.45M | 2.15M | 1.53M | 1.73M |
| Operating Income | -18.66M | -21.56M | -20.59M | -19.36M | -21.58M |
| Net Income | -17.09M | -20.1M | -19.31M | -17.88M | -19.8M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 6.01M | 6.91M | 10.99M | 39.02M | 18.14M |
| Operating Income | -144.07M | -57.33M | -73.52M | -65.46M | -78.1M |
| Net Income | -153.72M | -75.87M | -88.39M | -69.46M | -72.85M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 176.82M | 158.64M | 144.4M | 150.29M | 160.04M |
| Total Liabilities | 42.13M | 39.3M | 38.38M | 35.65M | 37.59M |
| Total Equity | 134.69M | 119.34M | 106.02M | 114.64M | 122.45M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 105.54M | 137.08M | 204.49M | 195.42M | 144.4M |
| Total Liabilities | 32.79M | 35.11M | 35.05M | 58.57M | 38.38M |
| Total Equity | 72.74M | 101.97M | 169.44M | 136.85M | 106.02M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -46.86M | -68.64M | -85.94M | -19.3M | -33.8M |
| Investing | 18.12M | 28.55M | 50.77M | 11.69M | 21.52M |
| Financing | 25.16M | 26.84M | 30.65M | 24.43M | 48.8M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -71.01M | -51.44M | -67.53M | -35.36M | -85.94M |
| Investing | 28.34M | -14.91M | -12.68M | -74.94M | 50.77M |
| Financing | 37.46M | 86.75M | 137.24M | 31.81M | 30.65M |
| Market Cap | 606.99M |
| Price to Earnings Ratio | -8.30 |
| Price to Sales Ratio | 33.37 |
| Price to Cash Ratio | 23.02 |
| Price to Book Ratio | 5.71 |
| Dividend Yield | - |
| Shares Outstanding | 191.48M |
| Average Volume (1 week) | 1.16M |
| Average Volume (1 Month) | 1.33M |
| 52 Week Change | 8.93% |
| 52 Week High | 4.725 |
| 52 Week Low | 2.63 |
| Spread (Intraday) | 0.34 (10.3%) |
| Company Name | Arbutus Biopharma Corporation |
| Address |
100 burnaby, british columbia V5J 5J8 |
| Website | https://www.tekmirapharm.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
